Repurposing screens identify rifamycins as potential broad-spectrum therapy for multidrug-resistant Acinetobacter baumannii and select agent microorganisms

Future Microbiology

Volumn 7, Issue 8, 2012, Pages 1011-1020

  Chromy, Brett A ^a,b   Elsheikh, Maher ^b   Christensen, Tova L ^b   Livingston, Doug ^c   Petersen, Kyle ^d   Bearinger, Jane P ^b   Hoeprich, Paul D ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LAWRENCE LIVERMORE NATIONAL LABORATORY   (United States)

^c Evotec San Francisco   (United States)

^d NAVAL MEDICAL RESEARCH CENTER   (United States)

Author keywords

Acinetobacter baumannii; Bacillus anthracis; Francisella tularensis; rifamycins; select agent pathogens; Yersinia pestis

Indexed keywords

AMIKACIN; AZTREONAM; BENZBROMARONE; CARMOFUR; CEFATRIZINE; CEFDINIR; CEFEPIME; CEFIXIME; CEFPODOXIME PROXETIL; CIPROFLOXACIN; CLARITHROMYCIN; CLOTRIMAZOLE; COTRIMOXAZOLE; DACTINOMYCIN; DISULFIRAM; EFAVIRENZ; EPIRUBICIN; GENTAMICIN; HONOKIOL; HYPERIN; IMIPENEM; INDATRALINE; LINEZOLID; OXICONAZOLE; PIPERACILLIN PLUS TAZOBACTAM; RIFAMYCIN; SULTAMICILLIN; TOREMIFENE; TRICLABENDAZOLE; UNINDEXED DRUG;

ACINETOBACTER BAUMANNII; ANTIMICROBIAL ACTIVITY; ASSAY; BACTERIAL GROWTH; BACTERIUM ISOLATE; CELL GROWTH; CELL RESPIRATION; CONTROLLED STUDY; DRUG SCREENING; FRANCISELLA TULARENSIS; KLEBSIELLA PNEUMONIAE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; SOLDIER; UNITED STATES; YERSINIA PESTIS;

ANTI-BACTERIAL AGENTS; BACTERIA; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; RIFAMYCINS;

ACINETOBACTER BAUMANNII; BACILLUS ANTHRACIS; BACTERIA (MICROORGANISMS); FRANCISELLA TULARENSIS; NEGIBACTERIA; YERSINIA PESTIS;

EID: 84865574615     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.12.75     Document Type: Review

References (28)

1. Kaitin KI, DiMasi JA. Measuring the Pace of new drug development in the user fee era. Drug Information Journal 34(3), 673-680 (2000
2. Chong CR, Sullivan DJ. New uses for old drugs. Nature 448, 645-646 (2007
3. Netterweld J. Recycling existing drugs. Drug Discov. Devel. 16-22 (2008
4. Collins FS. Mining for therapeutic gold. Nat. Rev. Drug Discov. 10(6), 395 (2011
5. Mody RM, Zapor M, Hartzell JD et al. Infectious complications of damage controlorthopedics in war trauma. J. Trauma 67, 758-761 (2009
6. Petersen K, Riddle MS, Danko JR et al. Trauma-related Infections in battlefield casualties from Iraq. Ann. Surg. 245, 803-811 (2007
7. Johnson, E. Burns TC, Hayda RA, Hospenthal DR, Murray CK. infectious complications of open type III tibial fractures among combat casualties. Clin. Infect. Dis.45, 409-415 (2007
8. Bossi P, Garin D, Guihot A et al. Bioterrorism: management of major biological agents. Cell Mol. Life Sci. 63, 2196-2212 (2006
9. Inglesby TV, Dennis DT, Henderson DA et al. Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA 283, 2281-2290 (2000
10. Dennis DT, Inglesby TV, Henderson DA et al. Tularemia as a biological weapon. JAMA 285(21), 2763-2773 (2001
11. Stenseth NC, Atshabar BB, Begon M et al. Plague: past, present, and future. PLoS Med. 5, e3 (2008
12. Lee VT, Schneewind O. Protein secretion and the pathogenesis of bacterial infections. Genes Dev. 15, 1725-1752 (2001
13. Perry RD and Fetherston JD. Yersinia pestis - etiologic agent of plague. Clin. Microbiol. Rev. 10, 35-66 (1997
14. Saslaw S, Eigelsbach HT, Wilson HE, Prior JA, Carhart S. Tularemia vaccine study, I: Intracutaneous challenge. Arch. Intern. Med. 107, 121-133 (1961
15. Saslaw S, Eigelsbach HT, Prior JA, Wilson HE, Carhart S. Tularemia vaccine study, II: Respiratory challenge. Arch. Intern. Med. 107, 134-146 (1961
16. Turnbull PC. Introduction: Anthrax history, disease and ecology. Curr. Top. Microbiol. Immunol. 271, 1-19 (2002) (2002
17. Passalacqua KD and Bergman NH. Bacillus anthracis: Interactions with the host and establishment of inhalational anthrax. Future Microbiol. 1, 397-415 (2006
18. Chopra S, Torres-Ortiz M, Hokama L et al. Repurposing FDA-approved drugs to combat drug resistant Acinetobacter baumannii. J. Antimicrob. Chemother. 65, 2598-2601 (2010
19. Gleeson T, Petersen K, Mascola J. Successful treatment of Acinetobacter meningitis with meropenem and rifampicin. J. Antimicrob. Chemother. 56, 602-603 (2005
20. Floss HG, Yu T-W. Rifamycin - mode of action, resistance and biosynthesis. Chem. Rev. 105, 621-632 (2005
21. Drapeau CMJ, Grilli E, Petrosillo N. Rifampin combined regimens for Gram-negative infections: data from the literature. Intl J. Antimicrob. Agents 35, 39-44 (2010
22. Durante-Mangoni E, Zarrilli R. Global spread of drug-resistant Acinetobacter baumannii: molecular epidemiology and management of antimicrobial resistance. Future Microbiol. 6(4), 407-422 (2011
23. Bochner BR. Global phenotypic characterization of bacteria. FEMS Microbiol. Rev. 33, 191-205 (2009
24. Fukuoka Y, Ikeda Y, Yamashiro Y, Takahata M, Todo Y, Narita H. In vitro and in vivo antibacterial activities of T-3761, a new quinolone derivative. Antimicrob. Agents Chemother. 37(3), 384-392 (1993
25. Sarkar-Tyson M, Atkins HS. Antimicrobials for bacterial bioterrorism agents. Future Microbiol. 6(6), 667-676 (2011
26. Gurgo C. Rifamycins. In: Handbook of Experimental Pharmacology. Born GVR, Cam PE, Caliguiri LA (Eds). Springer-Verlag, NY, USA, 519-555 (1982
27. Finland M, Garner C, Wilcox C, Sabath LD. Susceptibility of "Enterobacteria" to penicillins, cephalosporins, lincomycins, erythromycin, and rifampin. J. Infect. Dis. 134(Suppl. 1), S75-S96 (1976
28. Mandell GL, Bennett JE, Dolin R. Principles and Practice of Infectious Diseases, 7th Edition. Elsevier, NY, USA (2010